Proctor & Gamble Wins Actonel Patent Ruling

(CN) - The Federal Circuit upheld the validity of Proctor & Gamble's patent on the compound risedronate, the active ingredient in Actonel. The ruling blocks Teva Pharmaceuticals from making a generic version of the osteoporosis drug.

P&G sued Teva for patent infringement after Teva announced plans to make and sell a generic version of Actonel.

In defense, Teva argued that P&G's patent is invalid based on obviousness.

A federal judge in Delaware ruled for P&G, a decision the federal appeals court in Washington, D.C., affirmed.

Judge Huff concluded that risedronate was not obvious, and that P&G's patent "is not invalid for obviousness-type double patenting.

Subscribe to Closing Arguments

Sign up for new weekly newsletter Closing Arguments to get the latest about ongoing trials, major litigation and hot cases and rulings in courthouses around the U.S. and the world.

Email *

Submit